Johnson & Johnson MedTech, a leader in neurovascular care, announced today its upcoming data presentations and onsite activities at the 2025 Society of NeuroInterventional Surgery (SNIS) 22nd Annual… read more.
Neurocrine Biosciences, Inc. announced the release of findings from a new survey conducted by The Harris Poll highlighting the profound negative impact of tardive dyskinesia on patients and… read more.
The three most common reasons schools called emergency medical services (EMS) were for neurological crises such as seizures, psychiatric conditions or substance abuse, and trauma related injuries, according… read more.
An international study led by researchers at the University of Colorado Anschutz Medical Campus has identified a promising strategy to enhance the safety of nanomedicines, advanced therapies often… read more.
Celltrion announced that the FDA has approved Avtozma (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to Actemra. Avtozma is indicated for… read more.
A landmark 30-year study of over four million women in England has revealed that women with endometriosis-associated infertility are significantly more likely to become pregnant compared to those… read more.
Individual expectations about one’s health can influence him/her future condition and the speed of the progression of a disease: in fact, a research conducted by researchers of psychology… read more.
Edwards Lifesciences announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body… read more.
A new national study led by researchers at the University of Delaware and George Mason University highlights significant disparities in healthcare access for adults with disabilities during the… read more.
Cytokinetics, Incorporated (announced five presentations related to aficamten at the European Society of Cardiology Congress 2025 taking place in Madrid, Spain from August 29, 2025 – September 1,… read more.
The EMA has recommended granting a marketing authorisation in the European Union (EU) for Tepezza (teprotumumab), for the treatment of adults with moderate to severe thyroid eye disease…. read more.
Excessive physical exercise, especially without adequate rest, can damage the human body in various ways. In severe cases, it can progress to overtraining syndrome, which is characterized by… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
